MG1111 (Barycela inj.) — Competitive Intelligence Brief

MG1111 (Barycela inj.) (MG1111 (Barycela inj.)) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alpha fusion protein. Area: Virology / Immunology.

phase 3 Interferon alpha fusion protein Interferon alpha receptor (IFNAR) Virology / Immunology Biologic

Target snapshot

MG1111 (Barycela inj.) (MG1111 (Barycela inj.)) — GC Biopharma Corp. MG1111 is a recombinant human albumin-fused interferon alpha (IFN-α) fusion protein that enhances antiviral and immunomodulatory activity.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MG1111 (Barycela inj.) TARGET	MG1111 (Barycela inj.)	GC Biopharma Corp	phase 3	Interferon alpha fusion protein	Interferon alpha receptor (IFNAR)
GC3107	GC3107	Green Cross Corporation	phase 3	Interferon alpha fusion protein	Type I interferon receptor (IFNAR)
SIM0718 Injection	SIM0718 Injection	Simcere Pharmaceutical Co., Ltd	phase 3	Interferon alpha fusion protein	Interferon alpha receptor (IFNAR)
SL1002	SL1002	Saol Therapeutics Inc	phase 3	Interferon alpha fusion protein	Interferon alpha receptor (IFNAR)
STSP-0601 for Injection	STSP-0601 for Injection	Staidson (Beijing) Biopharmaceuticals Co., Ltd	phase 3	Interferon alpha fusion protein	Interferon alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alpha fusion protein class)

1. GC Biopharma Corp · 1 drug in this class
2. Green Cross Corporation · 1 drug in this class
3. Saol Therapeutics Inc · 1 drug in this class
4. Simcere Pharmaceutical Co., Ltd · 1 drug in this class
5. Staidson (Beijing) Biopharmaceuticals Co., Ltd · 1 drug in this class